Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer

• Publication date

  2014-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.28875PMID 24989332PMCID PMC6334650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PROceeding With the Patient-Reported Outcomes (PROs) Version of the Common Terminology Criteria for Adverse Events.

  2015cited by this paper
• Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

  2014cited by this paper
• Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

  2013cited by this paper
• Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

  2012cited by this paper
• Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

  2012cited by this paper
• Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

  2012cited by this paper
• Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma

  2011cited by this paper
• Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

  2011cited by this paper
• Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

  2010cited by this paper
• Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

  2010cited by this paper
• Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

  2010cited by this paper
• High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy

  2008cited by this paper
• Anti–Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts

  2007cited by this paper
• Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

  2007cited by this paper
• Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors

  2007cited by this paper
• Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion

  2007cited by this paper
• Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer

  2006cited by this paper
• Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice

  2006cited by this paper
• Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma

  2006cited by this paper
• Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

  2005cited by this paper
• Localization of Mesothelin in Epithelial Ovarian Cancer

  2005cited by this paper
• Vascular Endothelial Growth Factor in Predicting Outcome in Breast Cancer

  2004cited by this paper
• Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.

  2004influential reference
• Mesothelin

  2004cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003influential reference
• Mesothelin-family proteins and diagnosis of mesothelioma.

  2003cited by this paper
• Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

  2001cited by this paper
• Nonparametric Statistical Methods, 2nd, Ed.

  2001cited by this paper
• Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

  1996cited by this paper
• Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.

  1992cited by this paper

• Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy

  2025cites this paper
• Comparative theranostic efficacy of 177Lu- and 161Tb-labeled A1K2 SdAb in mesothelin-positive tumors.

  2025cites this paper
• Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma

  2025cites this paper
• Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations

  2025cites this paper
• First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors

  2025cites this paper
• Bacterial Protein Toxins as Anticancer Agents: Clinical Potential of Pseudomonas and Anthrax Toxins

  2025cites this paper
• Serum mesothelin as a response biomarker in pleural mesothelioma.

  2025cites this paper
• Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma

  2025cites this paper
• Unleashing precision: a review of targeted approaches in pleural mesothelioma.

  2024cites this paper
• Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.

  2024cites this paper
• Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma

  2024cites this paper
• Targeted Therapy in Mesotheliomas: Uphill All the Way

  2024cites this paper
• New insights on Pseudomonas aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery.

  2023cites this paper
• Targeted Approaches to Treatment of Pleural Mesothelioma: A Review

  2023cites this paper
• High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis.

  2023cites this paper
• The Origin and Fate of Liver Myofibroblasts

  2023cites this paper
• The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.

  2023cites this paper
• New Markers for Management of Mesothelioma

  2023cites this paper
• Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

  2023cites this paper
• High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma

  2023cites this paper
• Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates

  2023cites this paper
• Novel Oxygen-Dependent Degradable Immunotoxin Regulated by the Ubiquitin-Proteasome System Reduces Nonspecific Cytotoxicity.

  2022cites this paper
• The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury

  2022cites this paper
• Discovery of a novel human antibody VH domain with potent activity against mesothelin expressing cancer cells in both CAR T-cell and antibody drug conjugate formats

  2022cites this paper
• Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma

  2022cites this paper
• Characterization of Mesothelin Glycosylation in Pancreatic Cancer: Decreased Core Fucosylated Glycoforms in Pancreatic Cancer Patients’ Sera

  2022cites this paper
• Emerging trends in immunotoxin targeting cancer stem cells.

  2022cites this paper
• The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets

  2022cites this paper
• Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives

  2022cites this paper
• Discovery of a novel mesothelin specific human antibody VH domain

  2022cites this paper
• Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts

  2022cites this paper
• Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).

  2022cites this paper
• The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impact on the Diagnosis, Prognosis, and Therapeutic Target

  2022cites this paper
• Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights

  2022cites this paper
• Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells

  2022cites this paper
• Genome-Wide Identification of Rare and Common Variants Driving Triglyceride Levels in a Nevada Population

  2021cites this paper
• In silico analysis of STX2a-PE15-P4A8 chimeric protein as a novel immunotoxin for cancer therapy

  2021cites this paper
• Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin

  2021cites this paper
• The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis

  2021influential citation
• Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine

  2021cites this paper
• Immunotoxins: From Design to Clinical Application

  2021cites this paper
• In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin

  2021cites this paper
• Malignant peritoneal mesothelioma literature review: past, present, and future

  2021cites this paper
• Novel and Promising Systemic Treatment Approaches in Mesothelioma

  2021cites this paper
• Pleural mesothelioma (PM) - The status of systemic therapy.

  2021cites this paper
• Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis

  2021cites this paper
• Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology

  2021cites this paper
• Emerging biological therapies for the treatment of malignant pleural mesothelioma

  2021cites this paper
• Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model

  2021cites this paper
• Mesothelioma: is chemotherapy alone a thing of the past?

  2020cites this paper
• First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

  2020cites this paper
• Malignant pleural mesothelioma: current perspectives

  2020cites this paper
• Circulating biomarkers in malignant pleural mesothelioma

  2020cites this paper
• Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma

  2020cites this paper
• Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors

  2020cites this paper
• Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin

  2020cites this paper
• Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma

  2020cites this paper
• Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation

  2020cites this paper
• Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors

  2020cites this paper
• Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update

  2020cites this paper
• From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Clinical significance of histologic subtyping of malignant pleural mesothelioma

  2020cites this paper
• 18F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume

  2020cites this paper
• The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies

  2019cites this paper
• Reduction of non‐specific toxicity of immunotoxin by intein mediated reconstitution on target cells

  2019cites this paper
• Malignant Mesothelioma and Pseudomyxoma

  2019influential citation
• Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

  2019cites this paper
• Immunotherapy of Malignant Peritoneal Mesothelioma and Pseudomyxoma Peritonei

  2019cites this paper
• Malignant Pleural Mesothelioma: an Update for Pulmonologists

  2019cites this paper
• HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model

  2019cites this paper
• Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture

  2019cites this paper
• Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors

  2019cites this paper
• Biomarkers of Malignant Pleural Mesothelioma

  2019cites this paper
• The human tubal lavage proteome reveals biological processes that may govern the pathology of hydrosalpinx

  2019cites this paper
• Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

  2019cites this paper
• Mesothelin-Targeted Agents in Mesothelioma

  2019cites this paper
• Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives

  2019cites this paper
• Exosomes And Their Role In Asbestos Exposure And Mesothelioma

  2019cites this paper
• Mesothelin as a biomarker for targeted therapy

  2019cites this paper
• Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic

  2019cites this paper
• Related Peptide

  2019cites this paper
• Current treatments and trials in malignant pleural mesothelioma

  2018cites this paper
• Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia

  2018cites this paper
• Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma.

  2018cites this paper
• In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.

  2018cites this paper
• Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin.

  2018cites this paper
• Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.

  2018cites this paper
• Immunothérapie anti-tumorale dans le mésothéliome pleural malin

  2018cites this paper
• Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

  2018cites this paper
• Biomarkers in mesothelioma

  2018cites this paper
• Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment

  2018cites this paper
• Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.

  2018cites this paper
• Mesothelin as a target for cervical cancer therapy

  2018cites this paper
• Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

  2018cites this paper
• Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma

  2018cites this paper
• Immunotherapy for thoracic malignancies

  2017cites this paper
• Immunotherapy advances for mesothelioma treatment

  2017cites this paper
• Prognostication and monitoring of mesothelioma using biomarkers: a systematic review

  2017influential citation
• Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment

  2017cites this paper
• Protein-Based Therapeutic Killing for Cancer Therapies.

  2017cites this paper